Glioneuronal tumor with ATRX alteration, kinase fusion and anaplastic features (GTAKA): a molecularly distinct brain tumor type with recurrent NTRK gene fusions.
ATRX
DNA methylation
Gene fusion
Glioneuronal tumor
NTRK
Journal
Acta neuropathologica
ISSN: 1432-0533
Titre abrégé: Acta Neuropathol
Pays: Germany
ID NLM: 0412041
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
04
01
2023
accepted:
07
03
2023
revised:
07
03
2023
medline:
24
4
2023
pubmed:
19
3
2023
entrez:
18
3
2023
Statut:
ppublish
Résumé
Glioneuronal tumors are a heterogenous group of CNS neoplasms that can be challenging to accurately diagnose. Molecular methods are highly useful in classifying these tumors-distinguishing precise classes from their histological mimics and identifying previously unrecognized types of tumors. Using an unsupervised visualization approach of DNA methylation data, we identified a novel group of tumors (n = 20) that formed a cluster separate from all established CNS tumor types. Molecular analyses revealed ATRX alterations (in 16/16 cases by DNA sequencing and/or immunohistochemistry) as well as potentially targetable gene fusions involving receptor tyrosine-kinases (RTK; mostly NTRK1-3) in all of these tumors (16/16; 100%). In addition, copy number profiling showed homozygous deletions of CDKN2A/B in 55% of cases. Histological and immunohistochemical investigations revealed glioneuronal tumors with isomorphic, round and often condensed nuclei, perinuclear clearing, high mitotic activity and microvascular proliferation. Tumors were mainly located supratentorially (84%) and occurred in patients with a median age of 19 years. Survival data were limited (n = 18) but point towards a more aggressive biology as compared to other glioneuronal tumors (median progression-free survival 12.5 months). Given their molecular characteristics in addition to anaplastic features, we suggest the term glioneuronal tumor with ATRX alteration, kinase fusion and anaplastic features (GTAKA) to describe these tumors. In summary, our findings highlight a novel type of glioneuronal tumor driven by different RTK fusions accompanied by recurrent alterations in ATRX and homozygous deletions of CDKN2A/B. Targeted approaches such as NTRK inhibition might represent a therapeutic option for patients suffering from these tumors.
Identifiants
pubmed: 36933012
doi: 10.1007/s00401-023-02558-0
pii: 10.1007/s00401-023-02558-0
pmc: PMC10119244
doi:
Substances chimiques
ATRX protein, human
EC 3.6.4.12
Biomarkers, Tumor
0
Receptor Protein-Tyrosine Kinases
EC 2.7.10.1
X-linked Nuclear Protein
EC 3.6.4.12
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
667-680Informations de copyright
© 2023. The Author(s).
Références
Lancet Oncol. 2018 May;19(5):705-714
pubmed: 29606586
Acta Neuropathol. 2022 Mar;143(3):403-414
pubmed: 35103816
Brain Pathol. 2022 Jul;32(4):e13060
pubmed: 35218102
Acta Neuropathol. 2018 Aug;136(2):273-291
pubmed: 29564591
Acta Neuropathol. 2012 Nov;124(5):615-25
pubmed: 22886134
Acta Neuropathol. 2018 Aug;136(2):239-253
pubmed: 29766299
Acta Neuropathol. 2019 Sep;138(3):497-504
pubmed: 31250151
Acta Neuropathol. 2016 Jan;131(1):137-46
pubmed: 26482474
Acta Neuropathol. 2017 Mar;133(3):417-429
pubmed: 27812792
Cancer Discov. 2020 Jul;10(7):942-963
pubmed: 32238360
Nature. 2012 Jan 29;482(7384):226-31
pubmed: 22286061
Acta Neuropathol Commun. 2018 Jun 7;6(1):47
pubmed: 29880043
Acta Neuropathol. 2016 Jun;131(6):903-10
pubmed: 26671409
Acta Neuropathol. 2012 Oct;124(4):547-60
pubmed: 22810491
NPJ Precis Oncol. 2017 Mar 20;1(1):5
pubmed: 29872694
Acta Neuropathol. 2021 Nov;142(5):841-857
pubmed: 34417833
Acta Neuropathol. 2018 Aug;136(2):293-302
pubmed: 29978331
Acta Neuropathol. 2022 Dec;144(6):1179-1183
pubmed: 36121478
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
J Neuropathol Exp Neurol. 2014 Jun;73(6):580-4
pubmed: 24806303
Acta Neuropathol Commun. 2020 Aug 28;8(1):151
pubmed: 32859279
Acta Neuropathol. 2021 Nov;142(5):827-839
pubmed: 34355256
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Acta Neuropathol. 2019 Nov;138(5):827-835
pubmed: 31278449
Acta Neuropathol. 2022 Nov;144(5):1049-1052
pubmed: 36070143
Nat Rev Clin Oncol. 2018 Dec;15(12):731-747
pubmed: 30333516
Acta Neuropathol Commun. 2020 Jul 14;8(1):107
pubmed: 32665022
Nat Commun. 2019 Sep 25;10(1):4343
pubmed: 31554817
Neuropathol Appl Neurobiol. 2022 Oct;48(6):e12834
pubmed: 35836307